Ascend Wellness (AAWH) Q4 2024 earnings summary

Executive summary

• FY 2024 net revenue rose 8.3% year-over-year to $561.6M, driven by wholesale expansion, new dispensaries, and a renewed focus on profitability and cash generation.

• Cost-saving and transformation initiatives delivered $30M in annualized savings, supporting margin improvement and operational discipline.

• Share buyback program initiated, with 11M shares repurchased (~5% of outstanding) and further buybacks planned.

• Retail densification strategy underway, targeting a 50% increase in store base, with 10 new locations identified for 2025 and a strong pipeline in key states.

• Launched Effin', a new effect-based brand, quickly becoming a top edible at stores, and introduced new premium products.

Financial highlights

• FY 2024 net revenue reached $561.6M, up 8.3% year-over-year; Adjusted EBITDA up 9.1% to $116.2M.

• Q4 2024 net revenue was $136.0M, down 4% sequentially; Adjusted EBITDA rose 20.4% to $30.2M, with margin up 450 bps to 22.2%.

• Cash from operations in Q4 was $35.2M, marking the eighth consecutive quarter of positive operating cash flow; free cash flow was $30.1M.

• Cash and cash equivalents stood at $88.3M at year-end; net working capital improved to $84.8M.

• FY 2024 gross profit was $184.2M (32.8% margin); Adjusted Gross Profit was $225.9M (40.2% margin).

Outlook and guidance

• Q1 2025 expected to see a mid-single-digit percentage revenue decline due to softer consumer spending and weather impacts, but adjusted EBITDA margin is expected to remain above 20%.

• Densification strategy aims for 50% store base growth, with several new dispensaries expected in H2 2025.

• CapEx for 2025 projected at $30–$35M, with about half allocated to new store openings.

• Management expects to implement further cost savings and efficiency measures in 2025.

• Refreshed product offerings and menu optimization expected to drive topline growth and profitability in H2 2025.